The Difference Between Panitumumab and Bevacizumab

Panitumumab (Panitumumab) and bevacizumab (Cetuximab) are two commonly used targeted drugs that have been widely used in combination with chemotherapy for patients with wild-type RAS metastatic colorectal cancer (mCRC). However, they have some differences in structure, mechanism of action and clinical application.

1. Structurally: Panitumumab and bevacizumab are two different monoclonal antibodies. Panitumumab is a humanized IgG2 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) on tumor cells. Bevacizumab is also a human-mouse chimeric IgG1 monoclonal antibody that also achieves anti-tumor effects by binding to EGFR.

2. Indications: Although panitumumab and bevacizumab are both used to treat certain malignant tumors, they differ in specific indications. Panitumumab is primarily indicated for the treatment of patients with KRAS mutation-negative metastatic colorectal cancer and other tumor types identified as overexpressing EGFR. In addition to being used to treat colorectal cancer, bevacizumab can also be used to treat other types of tumors such as head and neck squamous cell carcinoma.

It is understood that the original version of panitumumab has not yet been launched in China, and therefore it has not been covered by medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around RMB 9,000 (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.